Meet Flu D, The Quiet Cattle Virus With Pandemic-Style Warning Signs: In December 2025, a U.S.–Mexican research team traveled to a massive Monterrey-area feedlot to track influenza D virus (IDV), a little-studied flu type whose main reservoir is cattle. Using nasal swabs, blood draws, and air samplers, they probed how the virus circulates in crowded pens and what animals—and workers—are exposed to. IDV has traits that echo influenza A: global spread, multiple host species, and an ability to reassort genetically, raising concern it could adapt toward humans. Antibodies have been found in livestock workers, and a recent preprint reports IDV can infect human airway cells, though definitive human infection remains unproven. Research and surveillance lag due to scarce funding and farmer reluctance, even as IDV may contribute to costly bovine respiratory disease. (Science)

Blood-Based “Stable CpGs” Become Unstable With Age—and Track Disease Risk: A large analysis identifies 31,744 CpG sites with highly consistent methylation patterns in the blood of young, healthy people, then tests how those “stable” loci behave across 8,886 individuals from 29 cohorts. The punchline: in blood cancers, methylation disruption at these sites tracks clonal dynamics and mutation burden across leukemia treatment; in non-cancer cohorts, methylation at the same loci becomes progressively more variable with age. That rising “epigenetic instability” is associated with higher cardiovascular risk and worse survival, suggesting a practical biomarker that links aging biology, maladaptive clonal hematopoiesis, and downstream disease. The work also tries to tame a classic epigenetics problem—context dependence—by focusing on loci that are unusually stable early in life. (Nature)

FDA Go-Ahead to Test Cellular Rejuvenation via Partial Epigenetic Reprogramming: Nature Biotechnology reports that the FDA has cleared a first-in-human test of a “cellular rejuvenation” strategy based on partial epigenetic reprogramming—an approach that aims to roll back some molecular hallmarks of aging without fully resetting cell identity. The piece frames the approval as a milestone for a field long dominated by mouse work and controversial longevity claims, while emphasizing how little is settled: what “rejuvenation” should mean clinically, which biomarkers matter, and how safety will be demonstrated given theoretical risks like tumorigenesis or loss of cellular state. The trial’s specifics (indication, delivery method, and endpoints) matter here, because regulators will likely demand hard functional outcomes in addition to epigenetic-clock movement. (Nature)

Epigenetic Age Acceleration in Young Adults With Congenital Heart Disease: A new open-access Clinical Epigenetics study asks whether congenital heart disease (CHD) is associated with faster “biological aging” as measured by DNA-methylation clocks. The authors analyze epigenetic age acceleration in young adults with CHD and compare patterns against expectations for chronological age, aiming to connect early-life cardiovascular burden with systemic aging biology. The clinical upside—if replicated—is risk stratification: a blood-based epigenetic readout that could help flag patients who might benefit from tighter surveillance or earlier preventive interventions. The study also sits in a growing literature trying to separate correlation (illness and its treatments shifting methylation) from mechanism (disease processes driving aging-like changes), which is crucial before clocks can guide care. (Springer)

Myasthenia Gravis and Biological Aging: Mendelian Randomization Links Telomeres, Epigenetic Clocks, and mtDNA: Another Clinical Epigenetics paper uses Mendelian randomization to probe whether biological-aging proxies—telomere length, epigenetic clocks, and mitochondrial DNA (mtDNA) copy number—have causal relationships with myasthenia gravis. Rather than treating methylation clocks as descriptive biomarkers, the study leverages genetic instruments to reduce confounding and reverse causality, asking which aging signals might sit upstream of disease susceptibility. This approach can clarify whether “accelerated aging” signatures seen in autoimmune conditions reflect downstream inflammation/treatment effects or shared causal pathways. Even when MR points to association, interpretation hinges on instrument validity and pleiotropy checks—so the value is as a directional map for follow-up biology and prospective cohorts, not a final mechanistic verdict.(Springer)

A New Method to Decode How DNA “Switches” Control Gene Activity: Researchers report an improved massively parallel reporter assay—described as “enhancer-enabled MPRA (e2MPRA)”—to test how regulatory DNA sequences act as switches that turn genes on or off. The method is positioned as a way to measure enhancer activity at scale and with more context than older assays, helping decode which non-coding variants actually change gene expression. That’s foundational for epigenetics and gene regulation: many disease-associated variants live outside genes, in regulatory regions whose effects depend on cell type and chromatin context. The article emphasizes that understanding these switches can illuminate development, disease mechanisms, and why the same DNA sequence can behave differently across tissues—exactly where epigenetic state and transcription-factor environment do the heavy lifting. (Phys.org)

A DNA–Histone Variant “Handshake” That Guides Methylation Patterns: A Feb. 19 bioRxiv preprint proposes a mechanistic link between the histone variant H2A.Z and de novo DNA methylation by DNMT3B, arguing that H2A.Z can act as a guide for methylation patterning. The authors frame the interaction as a way cells coordinate chromatin state (histone composition) with methylation placement—two layers of epigenetic information that are often measured together but mechanistically hard to connect. If the model holds up in peer review, it would sharpen our understanding of how methylation landscapes are established and maintained, and why certain genomic regions are targeted while others resist methylation. As with all preprints, the key details to watch are replication across systems and whether alternative explanations fit the same data. (ScienceDaily)

Perseverance Pinpoints Its Location at “Mala Mala” on Mars: NASA highlights a navigation and mapping milestone: Perseverance precisely localizes itself at a site nicknamed “Mala Mala” in Jezero Crater. These “where exactly are we?” updates are more than geography—they’re the scaffolding for planetary science claims. Accurate localization ties rover observations to orbital maps, improves route planning, and helps scientists connect rock textures and geologic contacts seen on the ground to the broader crater history. It also supports sample-return logic: when you cache material, you need a defensible chain of context—stratigraphy, position, and surrounding units—so future labs can interpret what the samples represent. Even small improvements in localization reduce ambiguity when correlating imagery, mineral detections, and terrain models across instruments and timescales. (NASA)

Why Peeling Tape Screeches: Anyone who has peeled tape knows the sharp squeal it makes. Researchers now explain the sound’s true source: microscopic cracks racing through the adhesive at supersonic speed. Tape peels in a slip–stick pattern, and during each “slip,” tiny cracks form perpendicular to the pulling direction and zip across the tape’s width. The team filmed the crack dynamics through a glass plate and used ultrafast imaging to detect shock waves in air. Contrary to their initial idea, no shock waves appeared while cracks traveled—only when they hit the far edge. Because the cracks move too fast for air to fill the voids they open, low-pressure pockets form and then collapse at the edge, releasing sharp shock-wave pulses. Understanding this could help design quieter packaging tape. (Science)